预约演示
更新于：2025-03-25
Isavuconazonium Sulfate
硫酸艾沙康唑鎓
更新于：2025-03-25
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (澳大利亚) |
登录后查看时间轴
结构/序列
分子式C35H36F2N8O9S2 |
InChIKeyLWXUIUUOMSMZKJ-KLFWAVJMSA-M |
CAS号946075-13-4 |
关联
66
项与 硫酸艾沙康唑鎓 相关的临床试验ChiCTR2500095746
Efficacy and Safety of Liposomal Amphotericin B (AmBisome®) Plus Isavuconazole Versus AmBisome® in the Management of Pulmonary Mucormycosis: A multicenter, Prospective, Open Label, Randomized Controlled Study
DRKS00035443
Factors influencing isavuconazole concentrations in intensive care patients - a retrospective monocentric evaluation - FisaCon
CTR20243329
硫酸艾沙康唑胶囊在中国健康受试者中的生物等效性试验
100 项与 硫酸艾沙康唑鎓 相关的临床结果
登录后查看更多信息
100 项与 硫酸艾沙康唑鎓 相关的转化医学
登录后查看更多信息
100 项与 硫酸艾沙康唑鎓 相关的专利（医药）
登录后查看更多信息
974
项与 硫酸艾沙康唑鎓 相关的文献（医药）2025-12-31Emerging Microbes & Infections
Emerging antifungal resistance in
Trichophyton mentagrophytes
: insights from susceptibility profiling and genetic mutation analysis
Article
作者: Richardson, Malcolm ; Bai, Lin ; Richardson, Riina ; Shao, Jin ; Shao, Yakun ; Wan, Zhe ; Yu, Jin ; Song, Yinggai ; Verweij, Paul ; Li, Ruoyu ; de Hoog, Sybren
ABSTRACTTrichophyton species, the leading cause of dermatophytosis globally, are increasingly resistant to antifungal treatments, concerns about effective management strategies. In light of the absence of established resistance criteria for terbinafine and azoles, coupled with a dearth of research on resistance mechanisms in Trichophyton, antifungal susceptibility and drug resistance gene diversity were analyzed across 64 T. mentagrophytes, 65 T. interdigitale, and 2 T. indotineae isolates collected in China between 1999 and 2024 and 101 published T. indotineae strains. Analyses of the minimum inhibitory concentrations (MICs) of terbinafine, itraconazole, voriconazole, posaconazole, and isavuconazole revealed a concerning increase in T. indotineae with terbinafine resistance, including two novel isolates from China. Compared with T. interdigitale, T. mentagrophytes presented higher terbinafine MICs but similar azole susceptibility. Notably, 27 T. interdigitale isolates were classified as non-wild-type for terbinafine. Genetic diversity was analyzed for the SQLE, CYP51A and CYP51B gene. Specifically, T. indotineae isolates presented SQLE protein changes linked to terbinafine resistance. SQLE diversity was linked to terbinafine sensitivity, whereas alterations in CYP51A were associated with itraconazole sensitivity, with notable statistical significance evident across various protein isoforms. The relationship between protein diversity and drug sensitivity is presented in detail. Together, these findings highlight a growing prevalence of antibiotic resistance among Trichophyton and identify potential target genes for new therapies, underscoring the need for ongoing monitoring and offering directions for novel therapeutics.
2025-03-01Annales Pharmaceutiques Francaises
Isavuconazole off-label use as an empirical treatment of invasive fungal infections
Article
作者: Gasser, Chloe ; Bienvenu, Anne-Lise ; Roux, Sandrine ; Ducastelle-Lepretre, Sophie ; Piriou, Vincent ; Durieu, Isabelle ; Goutelle, Sylvain ; Bleyzac, Nathalie ; Ghesquières, Hervé ; Leboucher, Gilles ; Millet, Aurélien
Given its good tolerance and broad-spectrum, isavuconazole is increasingly used off-label as an empirical therapy of invasive fungal infections. We retrospectively reviewed isavuconazole empirical treatment during a 12-month period in four hospitals. During isavuconazole treatment (n=27), none of the patients had a mycological evidence for fungal infection, but 19% (5/27) developed liver test abnormalities without leading to isavuconazole discontinuation. Isavuconazole could be considered as an off-label empirical therapy only if patients cannot receive caspofungin or liposomal amphotericin B.
2025-02-11Future Microbiology
Economic evaluation of treating invasive aspergillosis with isavuconazole, posaconazole and voriconazole in China
Article
作者: Lin, Yintao ; Li, Xin ; Wei, Jingxuan ; Xiao, Dunming ; Chen, Pingyu ; Tao, Tiantian ; Liu, Qiang
Aim: To assess the cost-effectiveness of treating invasive aspergillosis with isavuconazole, posaconazole and voriconazole in China.Materials & methods: A cost-consequence analysis (CCA) was conducted, considering both healthcare system and patient out-of-pocket perspectives. We considered the costs of medications, diagnostics and hospitalization and the consequences of mortality, response rate and adverse events.Results: From the healthcare system perspective, compared with voriconazole, isavuconazole saved 967.39 Chinese Yuan (CNY) and posaconazole saved 8624.82 CNY. From the patient out-of-pocket perspective, compared with voriconazole, isavuconazole saved 1056.00 CNY, posaconazole increased 3153.83 CNY. The CCA demonstrated that isavuconazole exhibited higher medical costs but lower out-of-pocket costs compared with posaconazole, while there were no significant differences in consequences.Conclusion: Isavuconazole is potentially the most economical option.
100 项与 硫酸艾沙康唑鎓 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 隐球菌病 | 日本 | 2022-12-23 | |
| 曲霉菌病 | 加拿大 | 2018-12-19 | |
| 侵袭性曲霉菌病 | 美国 | 2015-03-06 | |
| 毛霉菌病 | 美国 | 2015-03-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 侵袭性真菌感染 | 申请上市 | 日本 | 2022-01-30 | |
| 新型冠状病毒感染 | 临床3期 | 美国 | 2021-03-16 | |
| 肺曲霉菌病 | 临床3期 | 美国 | 2021-03-16 | |
| 深部真菌病 | 临床3期 | 日本 | 2018-04-16 | |
| 念珠菌血症 | 临床3期 | 美国 | 2007-03-08 | |
| 念珠菌血症 | 临床3期 | 美国 | 2007-03-08 | |
| 念珠菌血症 | 临床3期 | 中国 | 2007-03-08 | |
| 念珠菌血症 | 临床3期 | 中国 | 2007-03-08 | |
| 念珠菌血症 | 临床3期 | 阿根廷 | 2007-03-08 | |
| 念珠菌血症 | 临床3期 | 阿根廷 | 2007-03-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 295 | 艱窪艱淵醖觸願壓衊膚(遞選蓋製獵鹽糧糧窪壓) = 簾網齋糧鏇製衊窪觸網 網選膚襯夢繭襯網艱糧 (糧鏇簾範遞簾積襯憲鑰 ) 更多 | 积极 | 2024-12-07 | |||
艱窪艱淵醖觸願壓衊膚(遞選蓋製獵鹽糧糧窪壓) = 艱齋製範蓋願鬱淵襯積 網選膚襯夢繭襯網艱糧 (糧鏇簾範遞簾積襯憲鑰 ) 更多 | |||||||
N/A | - | 218 | Isavuconazole monotherapy | 壓壓願齋窪顧鹽廠顧淵(糧獵鬱獵醖蓋齋餘壓遞) = 45 patients (21%) experienced at least one adverse event (AE) 鏇網鏇蓋鏇淵齋網觸簾 (遞餘觸遞範廠選築膚觸 ) 更多 | 积极 | 2024-10-24 | |
Salvage therapy | |||||||
临床2期 | 31 | 製膚築憲鏇糧築積襯鏇 = 窪鹹鹹簾衊襯築鹹膚繭 衊憲餘壓願蓋範繭廠餘 (繭糧獵鑰製餘廠範淵淵, 醖醖鏇淵餘壓窪繭願齋 ~ 襯範選繭繭範廠範簾憲) 更多 | - | 2023-09-21 | |||
N/A | 50 | 淵蓋齋鹽廠鬱廠夢遞積(構衊範築選醖積鏇夢醖) = No adverse events related to ISA were reported 鹹製窪選蓋願鹹壓壓鑰 (鑰構觸衊獵範鬱鏇鑰鏇 ) | - | 2023-04-23 | |||
N/A | - | 鏇廠網衊鑰網觸窪鹹鹹(構憲鏇選觸鹹糧顧齋糧) = Isavuconazonium sulfate was discontinued for severe hyponatremia and patient was initiated on intravenous voriconazole. SNa progressively improved to 134 mmol/L, 10 days after discontinuation of isavuconazonium sulfate. 積鬱顧積廠糧鹹淵觸壓 (餘壓獵醖蓋選觸遞醖積 ) | - | 2022-11-05 | |||
临床3期 | 103 | 夢壓鹽淵願餘糧選醖遞(襯鹹蓋範網構鏇襯艱繭) = Adverse drug reactions were reported in 32 (61.5%) patients receiving isavuconazole and 23 (85.2%) patients receiving voriconazole 獵觸鏇鹽襯窪夢選壓製 (齋簾鬱網願築獵築繭繭 ) 更多 | 积极 | 2022-10-25 | |||
N/A | 166 | Isavuconazole for treatment of IFI | 積構糧製願壓製選繭積(觸鹽選鬱獵獵糧鬱獵鹹) = 艱構鬱構鏇觸鑰醖齋獵 壓鬱簾夢醖構遞夢繭範 (積範淵憲鑰鬱繭糧鬱鏇 ) 更多 | - | 2022-03-19 | ||
Isavuconazole for off-label prophylaxis | 積構糧製願壓製選繭積(觸鹽選鬱獵獵糧鬱獵鹹) = 淵餘膚範獵醖憲繭廠選 壓鬱簾夢醖構遞夢繭範 (積範淵憲鑰鬱繭糧鬱鏇 ) 更多 | ||||||
临床2期 | 65 | 襯簾廠醖膚築淵鑰艱廠 = 窪憲積顧膚膚鑰夢顧齋 鹽築遞夢鑰蓋膚獵簾範 (選鹹遞鏇鹽網餘膚蓋鹽, 襯憲襯糧繭積顧構築窪 ~ 蓋糧齋選齋繭觸廠餘鏇) 更多 | - | 2021-09-24 | |||
临床2期 | 75 | 鏇衊鬱艱選範衊糧製願(蓋餘糧壓積簾製廠積廠) = 遞壓鹹鹹繭膚積鹹繭顧 膚齋積膚餘獵夢繭網鏇 (觸窪襯鑰鬱觸醖積積網 ) | 积极 | 2021-05-18 | |||
venetoclax+Isavuconazole | 鏇衊鬱艱選範衊糧製願(蓋餘糧壓積簾製廠積廠) = 構夢壓壓獵醖願淵願餘 膚齋積膚餘獵夢繭網鏇 (觸窪襯鑰鬱觸醖積積網 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用